The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

According to TipRanks.com, Block is a 4-star analyst with an average return of 5.2% and a 49.7% success rate. Block covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute ...

Guardant Health thinks around 700,000 patients in the U.S. could eventually benefit from advanced-stage cancer screening, which would drive up sales to around $6 billion annually.